Knight Therapeutics (OTCMKTS:KHTRF) Shares Climb 3% – Time to Buy?

Knight Therapeutics Inc. (OTCMKTS:KHTRF) shares were up 3% on Monday. The company traded as high as $7.94 and last traded at $7.94. Approximately 1,400 shares traded hands during trading, a decline of 81% from the average session volume of 7,320 shares. The stock had previously closed at $7.71.

Wall Street Analysts Forecast Growth

Separately, Royal Bank Of Canada restated an “outperform” rating on shares of Knight Therapeutics in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Buy rating. Based on data from MarketBeat, the company has an average rating of “Buy”.

Knight Therapeutics Stock Up 3.0%

The stock has a fifty day moving average of $7.18 and a two-hundred day moving average of $6.61.

Knight Therapeutics Company Profile

Knight Therapeutics Inc is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative prescription medicines. The company targets areas of significant unmet medical need, including oncology, rare diseases, neurology, infectious diseases and other specialty-care markets.

Knight works with pharmaceutical and biotechnology partners to bring approved or late-stage therapies to patients. Its activities generally include regulatory support, market access, commercialization and distribution rather than large-scale discovery research.